Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR2 | P30518 | 17/20 | 0.36 |
| ▸ | AVPR1A | P37288 | 2/20 | 0.32 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6475611 | 0.87 | AVPR2 (0.40) | AVPR2AVPR1AGPBAR1 | |
| SCHEMBL6486438 | 0.85 | AVPR1A (0.37) | AVPR2AVPR1A | |
| SCHEMBL5106745 | 0.85 | AVPR2 (0.40) | AVPR2AVPR1A | |
| SCHEMBL5104645 | 0.82 | AVPR2 (0.51) | AVPR2AVPR1A | |
| SCHEMBL6207696 | 0.81 | PDK1 (0.39) | AVPR2AVPR1AGPBAR1 | |
| Citric Acid SCHEMBL5120144 | 0.80 | AVPR2 (0.44) | AVPR2AVPR1A | |
| Cadaverine Tartrate SCHEMBL6235311 | 0.79 | AVPR2 (0.37) | AVPR2AVPR1AGPBAR1 | |
| SCHEMBL6629386 | 0.77 | AVPR2 (0.46) | AVPR2AVPR1A | |
| SCHEMBL6475978 | 0.77 | AVPR2 (0.33) | AVPR2AVPR1A | |
| SCHEMBL6190961 | 0.77 | AVPR2 (0.40) | AVPR2AVPR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6977254-B2 | Hydroxy cyclohexenyl phenyl carboxamides tocolytic oxytocin receptor antagonists | WYETH (US) | 2005-12-20 | — | — | US | claimed |
| US-20020183311-A1 | Novel hydroxy cyclohexenyl phenyl carboxamides tocolytic oxytocin receptor antagonists | WYETH | 2002-12-05 | — | — | US | claimed |
| US-6977254-B2 | Hydroxy cyclohexenyl phenyl carboxamides tocolytic oxytocin receptor antagonists | WYETH (US) | 2005-12-20 | — | — | US | disclosed |
| EP-1385849-A1 | NOVEL HYDROXY CYCLOHEXENYL PHENYL CARBOXAMIDES TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | Wyeth (US) | 2004-02-04 | — | — | EP | disclosed |
| US-20020183311-A1 | Novel hydroxy cyclohexenyl phenyl carboxamides tocolytic oxytocin receptor antagonists | WYETH | 2002-12-05 | — | — | US | disclosed |
| WO-2002083679-A1 | NOVEL HYDROXY CYCLOHEXENYL PHENYL CARBOXAMIDES TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | WYETH (US) | 2002-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183311-A1 | Novel hydroxy cyclohexenyl phenyl carboxamides tocolytic oxytocin receptor antagonists | OXTR, HTR1E, HTR3E | AVPR2 46/4885AVPR1A 21/4885GPBAR1 593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.